XTX Topco Ltd Buys Shares of 4,012 United Therapeutics Co. (NASDAQ:UTHR)

XTX Topco Ltd purchased a new stake in shares of United Therapeutics Co. (NASDAQ:UTHR) in the second quarter, according to its most recent filing with the SEC. The firm purchased 4,012 shares of the biotechnology company’s stock, valued at approximately $1,278,000.

Several other institutional investors have also modified their holdings of the company. Renaissance Technologies LLC raised its holdings in United Therapeutics by 1.1% during the second quarter. Renaissance Technologies LLC now owns 2,174,692 shares of the biotechnology company’s stock worth $692,748,000 after purchasing an additional 22,978 shares during the last quarter. LSV Asset Management raised its stake in shares of United Therapeutics by 82.5% during the 2nd quarter. LSV Asset Management now owns 966,370 shares of the biotechnology company’s stock worth $307,837,000 after buying an additional 436,851 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in shares of United Therapeutics by 4.0% during the 2nd quarter. Dimensional Fund Advisors LP now owns 585,969 shares of the biotechnology company’s stock worth $186,656,000 after buying an additional 22,683 shares during the last quarter. Norges Bank acquired a new stake in United Therapeutics in the 4th quarter valued at about $100,519,000. Finally, Swedbank AB purchased a new position in United Therapeutics during the 1st quarter valued at about $97,316,000. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Insider Buying and Selling

In other United Therapeutics news, CEO Martine A. Rothblatt sold 3,600 shares of the company’s stock in a transaction dated Wednesday, July 3rd. The stock was sold at an average price of $312.48, for a total transaction of $1,124,928.00. Following the completion of the sale, the chief executive officer now directly owns 130 shares in the company, valued at $40,622.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, Director Nilda Mesa sold 266 shares of United Therapeutics stock in a transaction on Tuesday, June 25th. The shares were sold at an average price of $318.58, for a total transaction of $84,742.28. Following the transaction, the director now owns 5,107 shares in the company, valued at approximately $1,626,988.06. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Martine A. Rothblatt sold 3,600 shares of the company’s stock in a transaction on Wednesday, July 3rd. The stock was sold at an average price of $312.48, for a total transaction of $1,124,928.00. Following the sale, the chief executive officer now directly owns 130 shares of the company’s stock, valued at $40,622.40. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 110,922 shares of company stock valued at $36,541,398. 12.50% of the stock is currently owned by company insiders.

United Therapeutics Trading Up 0.5 %

Shares of UTHR stock opened at $353.00 on Friday. The firm’s 50-day simple moving average is $338.55 and its 200-day simple moving average is $290.39. The company has a debt-to-equity ratio of 0.02, a current ratio of 4.35 and a quick ratio of 4.18. United Therapeutics Co. has a 1-year low of $208.62 and a 1-year high of $366.08. The firm has a market cap of $15.70 billion, a P/E ratio of 16.69, a PEG ratio of 1.25 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, July 31st. The biotechnology company reported $5.85 earnings per share for the quarter, missing analysts’ consensus estimates of $6.33 by ($0.48). United Therapeutics had a return on equity of 18.82% and a net margin of 40.87%. The company had revenue of $714.90 million for the quarter, compared to analysts’ expectations of $691.87 million. During the same period in the prior year, the business earned $5.24 EPS. The business’s revenue for the quarter was up 19.8% on a year-over-year basis. As a group, equities analysts forecast that United Therapeutics Co. will post 24.86 EPS for the current year.

Analyst Ratings Changes

Several analysts have issued reports on the stock. Morgan Stanley downgraded shares of United Therapeutics from an “overweight” rating to an “equal weight” rating and upped their price target for the company from $310.00 to $321.00 in a report on Thursday, July 11th. HC Wainwright reaffirmed a “buy” rating and issued a $400.00 target price on shares of United Therapeutics in a research note on Thursday, August 1st. Oppenheimer raised their price target on United Therapeutics from $400.00 to $575.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 28th. LADENBURG THALM/SH SH downgraded United Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 1st. Finally, Wells Fargo & Company lifted their price objective on United Therapeutics from $350.00 to $380.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 20th. One research analyst has rated the stock with a sell rating, three have given a hold rating and ten have given a buy rating to the company. According to MarketBeat.com, United Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $350.36.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.